CareDx's (CDNA) "Neutral" Rating Reiterated at HC Wainwright

CareDx (NASDAQ:CDNA - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 62.13% from the stock's current price. HC Wainwright also issued estimates for CareDx's Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.26 EPS.

A number of other analysts also recently issued reports on the company. Wells Fargo & Company raised CareDx from an "underweight" rating to an "equal weight" rating and decreased their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. The Goldman Sachs Group decreased their target price on CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Finally, Stephens restated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, CareDx has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

CareDx Stock Up 0.2 %

NASDAQ:CDNA traded up $0.03 on Monday, reaching $15.42. 1,675,008 shares of the company's stock were exchanged, compared to its average volume of 876,817. The firm has a market capitalization of $858.60 million, a price-to-earnings ratio of -5.71 and a beta of 2.27. The business has a fifty day moving average of $17.87 and a 200-day moving average of $21.16. CareDx has a 52-week low of $12.53 and a 52-week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $84.69 million for the quarter, compared to analysts' expectations of $84.56 million. During the same period last year, the firm earned ($0.03) earnings per share. The company's revenue for the quarter was up 17.6% compared to the same quarter last year. As a group, equities analysts anticipate that CareDx will post -0.9 earnings per share for the current year.

Insider Buying and Selling at CareDx

In related news, Director Peter Maag sold 13,281 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the transaction, the director now owns 316,743 shares of the company's stock, valued at $5,457,481.89. This represents a 4.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christine Cournoyer sold 16,700 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total value of $235,971.00. Following the completion of the sale, the director now directly owns 37,045 shares of the company's stock, valued at approximately $523,445.85. This trade represents a 31.07 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,246 shares of company stock worth $469,498. 4.90% of the stock is currently owned by insiders.

Institutional Trading of CareDx

Several hedge funds and other institutional investors have recently made changes to their positions in CDNA. Vanguard Group Inc. increased its holdings in CareDx by 7.1% in the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after buying an additional 323,554 shares in the last quarter. Bamco Inc. NY increased its position in shares of CareDx by 17.6% in the fourth quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock valued at $47,258,000 after buying an additional 330,627 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of CareDx by 7.3% in the 4th quarter. Fred Alger Management LLC now owns 1,613,992 shares of the company's stock worth $34,556,000 after buying an additional 110,471 shares in the last quarter. Invesco Ltd. grew its stake in CareDx by 3.5% in the 4th quarter. Invesco Ltd. now owns 1,514,850 shares of the company's stock valued at $32,433,000 after acquiring an additional 51,160 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in CareDx by 15.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock worth $30,663,000 after acquiring an additional 196,298 shares during the last quarter.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.